Mankind Pharma (BOM:543904) E10: ₹0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543904 Mankind Pharma Ltd BOM:543904
90 GF Score
Price ₹2,491.45
GF Value ₹2,933.99
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Mankind Pharma E10?

Mankind Pharma BOM:543904 -2.10% 90 E10 is ₹0.00 as of Mar. 2026. GuruFocus rates BOM:543904 with a GF Score™ of 90/100 and a GF Value™ of ₹2,933.99 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Mankind Pharma's adjusted earnings per share data for the fiscal year that ended in Mar. 2026 was ₹46.280. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-19), Mankind Pharma's current stock price is ₹ 2491.45. Mankind Pharma's E10 for the fiscal year that ended in Mar. 2026 was ₹0.00. Mankind Pharma's Shiller PE Ratio of today is .


Mankind Pharma  (BOM:543904) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Mankind Pharma E10 Related Terms


Mankind Pharma E10 Historical Data

* Premium members only.

The historical data trend for Mankind Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mankind Pharma E10 Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mankind Pharma Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:543904 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mankind Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's Shiller PE Ratio falls into.


BOM:543904
90GF Score
Mankind Pharma Ltd BOM:543904
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mankind Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mankind Pharma's adjusted earnings per share data for the fiscal year that ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=46.28/164.2724*164.2724
=46.280

Current CPI (Mar. 2026) = 164.2724.

Mankind Pharma does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate it.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹0.00 mean?
Mankind Pharma (BOM:543904) has a E10 of ₹0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Mankind Pharma and its competitors.
Is Mankind Pharma's E10 too high?
Mankind Pharma's current E10 is ₹0.00. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's E10 compare to ZTS and UTHR?
Mankind Pharma's E10 of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Mankind Pharma and its competitors. Mankind Pharma's current E10 is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,933.99, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current E10 is ₹0.00. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current E10 is ₹0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mankind Pharma (BOM:543904) Overvalued in 2026?

Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued. The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,933.99. GuruFocus considers Mankind Pharma to be Modestly Undervalued.

Key valuation signals for BOM:543904:

  • E10: ₹0.00
  • GF Value™: ₹2,933.99 vs. price of ₹2,491.45 (15.1% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mankind Pharma Business Description

Other Exchanges MANKIND:India
Address 262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score

Get the complete analysis for BOM:543904

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,491.45
Price
₹2,933.99
GF Value